HUE044294T2 - Melanoma és tüdõ karcinóma kezelése Smad3 inhibitor alkalmazásával - Google Patents

Melanoma és tüdõ karcinóma kezelése Smad3 inhibitor alkalmazásával

Info

Publication number
HUE044294T2
HUE044294T2 HUE17199116A HUE044294T2 HU E044294 T2 HUE044294 T2 HU E044294T2 HU E17199116 A HUE17199116 A HU E17199116A HU E044294 T2 HUE044294 T2 HU E044294T2
Authority
HU
Hungary
Prior art keywords
melanoma
treatment
lung carcinoma
smad3 inhibitor
smad3
Prior art date
Application number
Other languages
English (en)
Inventor
Hui Yao Lan
Original Assignee
Univ Hong Kong Chinese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Chinese filed Critical Univ Hong Kong Chinese
Publication of HUE044294T2 publication Critical patent/HUE044294T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE17199116 2012-10-26 2013-10-28 Melanoma és tüdõ karcinóma kezelése Smad3 inhibitor alkalmazásával HUE044294T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261719114P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
HUE044294T2 true HUE044294T2 (hu) 2019-10-28

Family

ID=50544039

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE17199116 HUE044294T2 (hu) 2012-10-26 2013-10-28 Melanoma és tüdõ karcinóma kezelése Smad3 inhibitor alkalmazásával
HUE13849415A HUE038327T2 (hu) 2012-10-26 2013-10-28 Tüdõrák kezelése a SMAD3 inhibitor SIS3 felhasználásával
HUE19150641A HUE056898T2 (hu) 2012-10-26 2013-10-28 A rák kezelése SMAD3 inhibitorral

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE13849415A HUE038327T2 (hu) 2012-10-26 2013-10-28 Tüdõrák kezelése a SMAD3 inhibitor SIS3 felhasználásával
HUE19150641A HUE056898T2 (hu) 2012-10-26 2013-10-28 A rák kezelése SMAD3 inhibitorral

Country Status (9)

Country Link
US (3) US20140120116A1 (hu)
EP (3) EP2911661B1 (hu)
CN (2) CN104768546B (hu)
ES (3) ES2719435T3 (hu)
HK (2) HK1211835A1 (hu)
HU (3) HUE044294T2 (hu)
PL (3) PL2911661T3 (hu)
PT (3) PT3527213T (hu)
WO (1) WO2014063659A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176306A1 (en) * 2015-04-27 2016-11-03 Yale University Novel compositions useful for treating cancer, and methods using same
US20180221463A1 (en) * 2017-01-13 2018-08-09 The Chinese University Of Hong Kong Modified NK Cells and Uses Thereof
CN108619149A (zh) * 2018-05-30 2018-10-09 同济大学 Sis3在调控纤维化相关疾病中的应用
EP3833664A4 (en) * 2018-08-06 2022-06-08 Moexa Pharmaceuticals Limited SMAD3 INHIBITORS
CN110302197A (zh) * 2019-07-26 2019-10-08 安徽医科大学第一附属医院 一种与恩杂鲁胺治疗敏感性相关的lncRNA及其在恩杂鲁胺治疗***癌中的应用
CN112603919A (zh) * 2019-10-03 2021-04-06 香港中文大学 使用sis3纳米药物治疗癌症

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6013788A (en) * 1999-04-09 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad3 expression
US20030139366A1 (en) 2000-05-19 2003-07-24 Roberts Anita B. Inhibition of Smad3 to prevent fibrosis and improve wound healing
DK2128246T3 (da) 2001-04-19 2014-05-12 Univ California Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar.
JPWO2003037862A1 (ja) * 2001-10-30 2005-02-17 日本新薬株式会社 アミド誘導体及び医薬
GB0302315D0 (en) 2003-02-01 2003-03-05 Univ East Anglia Novel therapeutic target
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
AU2005230848B9 (en) * 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
WO2008022467A1 (en) 2006-08-25 2008-02-28 Mark Lautens 2-substituted azain doles and 2 substituted thienopyrroles, their precursors and novel processes for the preparation thereof
WO2008046964A2 (en) * 2006-10-16 2008-04-24 Panu Jaakkola Novel useful inhibitors
WO2009151600A2 (en) 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
KR20120000056A (ko) * 2009-02-11 2012-01-03 고쿠리츠다이가쿠호우진 도쿄다이가쿠 뇌 종양 줄기 세포 분화 촉진제, 및 뇌종양 치료제
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
EP2911661B1 (en) 2017-11-29
PL2911661T3 (pl) 2018-05-30
ES2893461T3 (es) 2022-02-09
US20140120116A1 (en) 2014-05-01
PT2911661T (pt) 2018-03-05
US11666565B2 (en) 2023-06-06
WO2014063659A1 (en) 2014-05-01
HK1211835A1 (en) 2016-06-03
EP3527213A1 (en) 2019-08-21
ES2719435T3 (es) 2019-07-10
US20160279123A1 (en) 2016-09-29
HK1254307B (zh) 2020-03-20
CN104768546B (zh) 2019-04-19
PT3527213T (pt) 2021-10-14
CN110101862B (zh) 2022-11-01
EP2911661A4 (en) 2016-07-20
EP2911661A1 (en) 2015-09-02
EP3320906A1 (en) 2018-05-16
CN104768546A (zh) 2015-07-08
HUE038327T2 (hu) 2018-10-29
EP3527213B1 (en) 2021-07-07
PL3527213T3 (pl) 2022-01-03
PL3320906T3 (pl) 2019-07-31
HUE056898T2 (hu) 2023-06-28
US20230338361A1 (en) 2023-10-26
PT3320906T (pt) 2019-04-30
EP3320906B1 (en) 2019-01-09
CN110101862A (zh) 2019-08-09
ES2660739T3 (es) 2018-03-26

Similar Documents

Publication Publication Date Title
IL272921B (en) Combined treatment including a b-raf inhibitor and a second inhibitor
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HK1254307B (zh) 使用smad3抑制劑對黑色素瘤和肺癌的治療
EP2895083A4 (en) LIGATOR AND METHOD FOR ITS USE
EP2890678A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
EP2890679A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
SG11201406894VA (en) Oilfield apparatus and methods of use
EP2935283A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2914604A4 (en) GLYCOSIDASE INHIBITORS AND ASSOCIATED APPLICATIONS
EP2890676A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890675A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
SG11201406895QA (en) Oilfield apparatus and methods of use
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1206282A1 (en) Tfpi inhibitors and methods of use tfpi
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
HK1206257A1 (en) Use of vegfr-3 inhibitors for treating hepatocellular carcinoma vegfr-3
EP2939668A4 (en) PDK4 INHIBITOR AND USE THEREOF